Discountdown
Cancer-Drug Prices Are at a Tipping Point
A wave of recent FDA approvals should start to drive down costs.
This article is for subscribers only.
Cancer drugs generate a great deal of outrage with their six-figure price tags for vulnerable patients. Until now, they've faced little in the way of price competition.
That finally might be set to change with a recent wave of FDA approvals.